PHASQ stock falls 99.00% on 04 Feb 2026: top loser with delisting risk

PHASQ stock opened the U.S. PNK market at USD 0.000001 on 04 Feb 2026 after a one-day drop of 99.00% during market hours. Trading volume was light at 2,500 shares versus an average of 22,310, and the security is flagged as potentially delisted. This rapid decline follows Chapter 11 restructuring and low liquidity, pushing PhaseBio Pharmaceuticals, Inc. (PHASQ) into the top losers list today. We use Meyka AI’s real-time signals and public filings to explain the move and the near-term outlook.

PHASQ stock price action and market context

PhaseBio Pharmaceuticals, Inc. (PHASQ) traded at USD 0.000001 on the PNK exchange in the United States with a one-day change of -99.00%. Volume was 2,500 shares, well below the 50-day average of 22,310, reflecting severe liquidity stress. The company remains in the Healthcare sector and Biotechnology industry, and recent mentions show potential delisting concerns listed by market trackers MarketBeat.

PHASQ stock fundamentals and ratios

Latest reported EPS is -2.14, and the TTM operating margins are negative, consistent with a clinical-stage biotech. Key ratios show a current ratio near 1.75 and cash per share about 1.42, but shareholders’ equity per share is deeply negative at -3.16. These metrics underline that PhaseBio’s balance sheet and negative earnings leave little buffer against delisting and dilution risks.

PHASQ stock technicals and liquidity concerns

Price averages are vanishing: a 50-day average of 0.000236 and 200-day average of 0.000666 show the long slide. The daily trading range today was fixed at the penny tick (USD 0.000001), demonstrating extremely thin order books. Low relative volume and a market cap reported as 0 in data feeds indicate market makers may have withdrawn support, elevating volatility and execution risk.

Meyka AI grades and analyst view for PHASQ stock

Meyka AI rates PHASQ with a score of 58.91 out of 100 (Grade C+, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. This grade is informational only and not financial advice. The low score reflects weak liquidity, negative earnings, and delisting risk.

PHASQ stock forecast and price target outlook

Meyka AI’s forecast model projects USD 0.00, compared with the current price USD 0.000001, implying an effective downside to zero in the model scenario. Forecasts are model-based projections and not guarantees. No independent analyst price targets are available; given the Chapter 11 history and trading status, realistic scenarios range from recovery above USD 0.0001 in a rare restructuring recovery to permanent loss of value if delisting occurs.

Risks, catalysts, and trading strategy for PHASQ stock

Primary risks include a delisting action, further dilution from restructuring, and persistent negative cash flow. A catalyst would be a confirmed exit from bankruptcy with capital injection or a credible commercial partner for PB2452. For traders, the stock qualifies as a high-risk speculative play; position sizing and stop rules are essential if considering exposure on PNK in USD.

Final Thoughts

PHASQ stock is a clear top loser in market hours on 04 Feb 2026, trading at USD 0.000001 with a one-day fall of 99.00% and thin volume of 2,500 shares on the PNK exchange in the United States. Fundamentals show negative EPS (-2.14) and a deeply negative book value per share, while liquidity metrics and potential delisting flags heighten downside risk. Meyka AI rates PHASQ 58.91/100 (C+, HOLD) and its model currently projects USD 0.00, implying severe downside versus the present price; forecasts are model-based and not guarantees. Investors should treat PHASQ as a distressed biotech with binary outcomes: recovery only with successful restructuring or partner-backed clinical progress, or near-total loss if delisting and liquidation proceed. For more on the company and filings see PhaseBio’s website and the MarketBeat summary, and check Meyka AI’s live PHASQ page for updates and alerts.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.